The study results revealed that the On-X Prosthetic Heart Valve provided favorable intermediate-term results with regard to major thromboembolism, hemorrhage and composites of valve-related complications.
During the study, patients who were implanted with On-X valves between 2003 and 2008 were evaluated for thromboembolic and hemorrhagic complications.
The results demonstrated that combined event rates observed in aortic and mitral valve patients were below those seen in similar studies involving both mechanical and tissue valves.
On-X Life president and CEO Clyde Baker said these results reflect the difference between the composite morbid event rates with the On-X valve when compared to competitors documented rates of complications.
"In this study, On-X valve patients had up to 66% fewer complications compared with competitive valves," Baker said.
On-X Life is currently conducting study in the US to determine if patients implanted with the On-X valve can be safely maintained with reduced levels of warfarin anticoagulation or eliminate the use of warfarin altogether.
